Key result
Ajmaline infusion during Brugada testing provokes malignant wide QRS tachycardia in ~1% of cases.
Why the study?
The sodium channel blocker test used to diagnose Brugada syndrome carries a risk of malignant ventricular arrhythmias in 0.5%–1% of cases.
Ajmaline infusion for Brugada syndrome testing can induce atypical ventricular arrhythmias, highlighting the need for caution and monitoring during the procedure.
May warrant enhanced monitoring during ajmaline challenge; case report leaves open optimal prevention strategies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Laporte et al. (2025) studied this question. Ajmaline infusion during sodium channel blocker testing for Brugada syndrome induced an atypical wide QRS monomorphic tachycardia, a malignant arrhythmia risk seen in 0.5% to 1% of cases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: